5.ดร.ภญ.พรทิพย์ วิรัชวงศ์_GPO_Success_Vaccine_Development.pdf

1、GPO SUCCESS IN VACCINE DEVELOPMENTBuilding Sustainable Success for Vaccine Security“GPO:Driving Sustainable Vaccine Security”GPO is committed to advancing vaccine development to protect public health and enhance pandemic preparedness.GPOs MissionKey Vaccine ProjectsGPO has developed vaccine projects

2、 addressing critical diseases,highlighting self reliance and vaccine security.Global CollaborationsCollaborations with international organizations strengthen GPOs expertise and reach global recognition.Infrastructure and ImpactGPOs advanced infrastructure supports large-scale vaccine production impa

3、cting public health outcomes.2Key Vaccine Projects3Thailands first domestically developed and registered COVID-19 vaccine produced by egg-based platform.NDV-HXP-SCOVID-19 VaccineGPO produces seasonal trivalent and pandemic influenza vaccines tostrengthen national pandemic preparedness.Influenza Vacc

4、ineProduction1.HXP-GPOVac2.Influenza Vaccines4OUR CURRENT TECHNOLOGY Egg-based Technology Inactivated/Live vaccine Formulation Filling:Vials(2R,6R),Pre-filled syringe(1 mL)Liquid dosage formDRUG SUBSTANCE PRODUCTIONDRUG PRODUCT PRODUCTION5Sustainable Logistics6GPO Egg-based PlatformVirusPropagationP

5、urificationSplittingInactivationMONOVALENT BULKFINISHED PRODUCTSeasonalInfluenza strains(WHO recommendation)VirusPropagationPurificationInactivationNDVS HexaProTrivalentSplit virionMonovalentWhole virion+/-AdjuvantSEASONALINFLUENZAVACCINECOVID-19VACCINEFill-finished productFrom Up-stream to Down-str

6、eamFluvac H5ProductsModalityLicenseGPO CellFluTrivalent seasonal influenza vaccine,subunit inactivated,cell cultureFull MA26 Sep 2024GPO-4 CellFluQuadrivalent seasonal influenza vaccine,subunit inactivated,cell cultureFull MA11 Dec 2025GPO-CellFluGPO-4CellFlu Tri FluvacHXP-GPOVac